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Abstract
The delineation of the target volume, i.e. the volume which should be irradiated with a therapeutic dose of irradiation,
is of utmost importance in radiotherapy. Modern imaging techniques cannot be missed in this process. Diagnosticians
and radiation oncologists therefore should understand each other’s needs and potential.
Keywords: Radiotherapy; treatment planning; target volumes; biological target volume.
Staging for radiotherapy
Radiotherapy like surgery is a treatment for locoregional
tumour growth. So, imaging modalities are extremely
important for staging. Computerized tomography (CT),
ultrasonography and magnetic resonance imaging (MRI)
are used in the work-up of many tumours, e.g. in
cervical cancer and head and neck tumours to detect
lymph nodes, in rectal cancer to judge whether a free
margin can be obtained to make the patient a suitable
candidate for short term irradiation followed by surgery.
New imaging modalities are also being introduced for
staging such as fluorodeoxy glucose positron emission
tomography (FDG-PET) scanning in lung cancer and MR
lymphography with nanoparticles in prostate cancer.
Image guided radiotherapy volumes
Whereas surgery is tumour eradication under direct
vision, radiotherapy is tumour eradication under indirect
vision. So, imaging is of extreme importance for
radiotherapy planning. In radiation oncology the target
volume is that part of the body where a therapeutic dose
of irradiation should be applied. This target volume is
subdivided into several subsets: the gross tumour target
volume (GTV), the clinical target volume (CTV) and
the planning target volume (PTV). The GTV and CTV
have a biological background. The GTV is what you
can see, measure or palpate. The CTV is the suspected
microscopic extension of the disease, and as in surgery,
radiation oncologists also take a margin around the
visible tumour. The GTV can include regional lymph
nodes when microscopic spread to lymph nodes is
expected; and when they should be treated electively,
one could consider this as a nodal CTV. The PTV is a
geometric and not a biological concept. This volume by
two margins takes into account organ movement (internal
margin) and positioning in accuracies and inaccuracies
of the irradiation delivering equipment (set-up margin).
The PTV is created to ensure that the therapeutic dose is
indeed delivered to the CTV.
Although one could imagine that the delineation of the
GTV is most simple, we have to realise that different
imaging modalities ‘see’ tumours or organs differently,
e.g. the size of the prostate is different on MRI than
CT. What is the truth? Often radiation oncologists use
both. Consequently image registration or image fusion
has become of paramount importance. Like surgery, in
radiotherapy we also do some harm to normal tissues.
Healthy tissue is unavoidably irradiated. However, the
radiation dose in these tissues should be kept below
tolerance which means below the dose which creates
clinically manifest severe damage. For this reason a
fourth volume in the irradiated part of the body has to
be taken into account: the volume around an organ at
risk. This is the planning organ at risk volume (PRV). For
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example, when very high doses are given to the prostate,
one has to identify the PRV of the rectum. With the use
of so-called dose volume histograms, an impression can
be obtained of the percentage of the rectum receiving a
certain percentage of the total dose which correlates with
the risk of complications.
Volume delineation
To define the target volumes many radiotherapy depart-
ments now use their own dedicated CT scanners. One has
to realize that these scanners are different from diagnostic
ones. They have a larger aperture to allow for scanning in
treatment position and they have a flat table top. Also the
scanning protocols can be different from the diagnostic
ones. Planning scans are performed without the use of
contrast so as not to disturb the physiological size and
density of some of the organs. Scanning times might
be different, e.g. slower to detect lung movements and
also the slice distance may be different, usually 3 mm,
to obtain a reliable digitally reconstructed radiograph
(DRR). So, planning scans are not diagnostic scans and
one should be careful about using them for diagnostic
purposes. Furthermore, diagnostic scans are not planning
scans and one should be careful about using them without
certain precautions for treatment planning.
Intensive collaboration between the imaging depart-
ments and radiotherapy departments is necessary nowa-
days for radiation oncology. It would be advisable
to collaborate with a dedicated diagnostician who
understands the needs of the radiation oncologist. Proper
diagnostic reports should contain the information of
importance for the radiation oncologist, meaning that
the slices on which the GTV can be seen should be
mentioned in the diagnostic report. On the other hand, the
radiation oncologist should increase his/her knowledge in
diagnostic imaging by additional training as resident and
as part of a CPD (continuing professional development)
programme. Because different types of images are used
and have to be matched with the planning CT slices,
image registration has become an important part of the
volume delineation process. Image registration can be
performed by the use of anatomical landmarks but also
with the use of gold markers which are used in prostate
cancer GTV delineation.
Apart from the dedicated planning CT scanners,
radiation oncologists also make use of a simulator
consisting of a traditional X-ray apparatus, in some
cases provided with a CT extension with which low
quality CT slices can be made; these are sufficient for
the contouring of the patient. Essential in all these
simulation or localization procedures is that the images
are acquired in relation to a three-dimensional (3-D) set
of co-ordinates. Skin markers make it possible to position
the patient in a reproducible manner, making it possible to
deliver the treatment dose in a large number of fractions
over a substantial overall treatment time, e.g. 35 fractions
in 7 weeks. Dose plans finally are created on the basis of
the delineated volumes in relation to the co-ordinates.
Biological image guided radiotherapy
The tumour cell density might not be the same throughout
a tumour or an organ with a tumour. To date in the
treatment of prostate cancer the whole organ is treated
with a homogeneous dose while in many patients one
could identify a dominant intratumoral lesion (DIL) with
modern imaging techniques. It is logical to suppose that
the irradiation dose in the DIL should be higher than in
the rest of the prostrate and so a fifth volume can be
introduced: ‘the biological target volume’ (BTV).
Similarly, areas with other biological properties could
be identified such as hypoxic areas or rapidly prolif-
erating areas in order to adapt the dose distribution
accordingly. A new horizon is looming for all kinds of
biological imaging using new isotopes for PET scanning
and with the use of MR spectroscopy. Combined PET/CT
scanners could facilitate the necessary image registration
with reference to the co-ordinates. The developments
in imaging techniques and radiotherapy equipment have
written the history of radiotherapy in the past 30 years,
from an uncontrolled inhomogeneous dose distribution
via a controlled homogeneous distribution towards a
controlled inhomogeneous dose distribution in biological
image guided radiotherapy.
Target volume delineation on breast
cancer and breast cancer treatment
The role of radiotherapy in breast cancer is as an adjuvant
to surgery. Either the breast is removed by mastectomy or
the tumour only as part of a breast conserving procedure.
Consequently, the target volume only is a CTV. In breast
conserving therapy the tumour bed after lumpectomy
usually receives a higher dose. The visualization of this
tumour bed is still not optimal and usually the only way
is the use of radio-opaque clips which can interfere with
follow-up MRI scans. Research to develop better methods
is urgently required.
Conclusion
In the second half of the last century radiology in many
countries split into radiotherapy and radiodiagnostics and
imaging as independent specialties. Today the interaction
of our disciplines is more intensive than ever which
creates the need to understand each other’s needs and
potential.
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Abstract
There has been rapid acceptance of sentinel lymph node biopsy into the management of breast cancer over the past 10
years. This article seeks to highlight the controversies and to summarise its current status.
Keywords: Sentinel lymph node; breast cancer.
Introduction
The prognosis of breast cancer is determined primarily
by axillary lymph node status [1–3]. Axillary lymph node
dissection (ALND) surgery carries a significant morbidity
with complications such as lymphoedema, pain, numb-
ness and limited shoulder movement [4–6]. The sentinel
node is the first draining node on the direct drainage
pathway from the primary tumour site [7]. If the sentinel
node is positive there is a 40% risk that higher order nodes
may also be involved with metastatic disease [8]. Sentinel
lymph node biopsy (SLNB) is a minimally invasive
alternative to ALND for nodal staging in breast cancer.
The technique assumes orderly progression of tumour
spread to the regional nodes; and biopsy of the first
node in the lymphatic chain at risk for metastasis should
therefore reflect involvement of the remaining nodes.
Although no results from randomised trials validating
SLN biopsy in breast cancer are yet available, excellent
clinical outcomes using different protocols have been
achieved in over 20 000 patients studied to date [8].
Comparison of the results of SLNB with ALND has
shown that the sentinel node is representative of the
presence or absence of metastases in the remainder of the
nodal basin (with a false negative rate of less than 2%
in most series) [9–13]. Other prospective studies have also
validated the concept [14–18].
Technical issues
Lymphoscintigraphy
A large choice of dyes and radiopharmaceuticals (usu-
ally 99mTc sulphur colloid) are available. The colloid
employed should be of a size to be taken up efficiently
and retained within the sentinel node. It has been shown
that the highest counts in recovered sentinel nodes
were from 100–200 nm albumin colloid particles [19].
Filtered 99mTc sulphur colloid (100 nm filtered) has a
faster transport rate to the regional nodes and lower
radiation dosimetry. As a result it is the preferred
choice if performing surgery within 2 h of injection [8].
The sentinel node is more successfully identified with
radiopharmaceuticals than with dyes but a combined
technique using both maximises the potential of accu-
rate staging [15,20–22]. Preoperative lymphoscintigraphy
enables faster location of radioactive nodes at surgery
and the combined approach results in identification and
harvesting of more nodes [23,24]. The injection technique
seems to matter little as axillary nodes stained blue
by intradermal, peritumoural, subdermal, periareolar and
subareolar injections identify the same nodes [21,25–27].
It also appears that there is often more than one
sentinel lymph node and using dual agents will assist
in identifying all sentinel nodes. In a prospective multi-
institutional study of 1436 patients, the false negative
rate was 14.3% if a single sentinel lymph node was
removed compared with 4.3% if multiple sentinel lymph
nodes were removed indicating that there is often more
than one sentinel node [28]. Despite variation in mapping
techniques results have been similar worldwide with
sensitivity and diagnostic accuracy rates greater than 95%
and false negative rates ranging from 0 to 10% [29]. Some
breast cancer programmes do not routinely utilize preop-
erative lymphoscintigraphy because of the added time,
expense and the fact that the surgical decision making
can be performed intraoperatively [8]. Others advocate the
concept of the triple technique comprising preoperative
lymphoscintigraphy, and injection of radiotracer with
the use of a hand probe and blue dye [30]. Variables
such as availability of resources, patient numbers,
level of competence and local working practices mean
that no standard protocol exists. Nonetheless, it is
recognised that identification of the sentinel node in
greater than 96% of patients and a false negative rate
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of less than 5% is a desirable outcome [10,31,32]. Using
lymphoscintigraphy the surface location of the sentinel
node can be marked with some centres marking all
sentinel nodes visualised [33,34]. Although high resolution
collimators should be used, a medium energy collimator
will suffice [34]. The camera is placed as close to the
patient as possible and images should be acquired in
at least two planes. If the site of injection is close
to the nodes, shielding may be necessary to visualise
the sentinel node. In one centre analysing the results
of 640 patients, 94% demonstrated a sentinel node in
the ipsilateral axilla but 46% also had sentinel nodes
outside the axilla [34]. The most important site of extra-
axillary drainage was to the internal mammary nodal
chain and 40% of patients demonstrated a sentinel
node in this area [34]. In 5% of patients, drainage was
exclusively to extra-axillary sentinel nodes. Preoperative
lymphoscintigraphy enables these nodes to be identified.
Site of injection
Several theories exist concerning lymph node drainage in
the human breast [35]. Although Sappey described flow
to the subareolar plexus and then to the axilla, this
view was not universally accepted [36]. An alternative
drainage pattern proposed direct drainage to the ipsi-
lateral axilla avoiding the subareolar plexus [35,37]. A
recent study of 145 dynamic lymphoscintigrams using
both intraparenchymal and subdermal injections was
unable to visualise the subareolar plexus indicating
that it may not act as a conduit to the ipsilateral
axilla [38]. Variable drainage patterns from injections of
localising agents into the subareolar plexus, subdermal
breast tissue and the deep breast parenchyma have been
demonstrated by several groups [39–42]. Seven sites of
injection have been described (peritumoural, subdermal,
periareolar, intratumoural, intradermal, subareolar and
subtumoural) and one of the factors dictating choice
is the intention to locate internal mammary nodes in
addition to axillary nodes [43]. Peritumoural injections
were the first type of injection used [44,45]. Some groups
claim better success with intradermal injections than with
peritumoural technique when sulphur colloid and blue
dye are used [46]. Internal mammary node drainage occurs
in a significant proportion after peritumoural injection
but not after intradermal injection [47]. However, the
intradermal technique has been shown to identify the
SLN in the axilla with a frequency of 98% compared
with 90% for peritumoural parenchymal technique [10,48].
Periareolar injections are made just outside the areolar
border at four equally spaced sites. The injections
are subdermal though a single subareolar injection
lined up with the tumour can also be used [26,27,49].
This technique militates against extra-axillary node
identification but is easy and efficient [50–52]. Using a
combination of radioisotope and blue dye, the SLN
was identified successfully in 98% of cases with no
false negative results [53]. Subareolar injection of blue
dye alone has been shown to demonstrate a sentinel
lymph node in 98% of cases with no false negative
sentinel nodes [50,54]. Likewise, it has been shown that
subareolar injection of technetium is equivalent to
peritumoural injection of blue dye [55,56]. One centre
uses the combined intraparenchymal and subdermal
injection technique because it more accurately reflects all
lymphatic flow from breast tumour [38]. Intraparenchymal
injections consistently visualise a more diverse pattern of
lymph flow. In particular, the internal mammary chains
and supraclavicular nodes are commonly seen after
intraparenchymal injection but rarely after subareolar
or subdermal injections. Peritumoural and subdermal
injection of 99mTc sulphur colloid combined with
periareolar injection of isosulphan blue dye is advocated
by another group with extensive experience [32,57–59].
Overall, the identification rate, accuracy and predictive
value of sentinel node biopsy seem to be unaffected by the
site of injection though a difference may become apparent
with long-term follow-up that examines the pattern of
axillary failure correlated with the injection site [13].
When should injection be performed?
Comparable accuracies have been shown for same day
and day before surgery radioisotope injections [60,61].
After injection breast massage may be performed to
augment lymphatic flow [62]. However, concern exists
that tumour cells might be transported from the primary
tumour into the lymphatics. Pressure within the lym-
phatics can increase up to 22-fold following external
massage and transport of tumour cells to the lymphatic
spaces has been demonstrated [63–65]. However, isolated
tumour cells are not true metastases and do not have
malignant potential. Intraoperative injection is little used
as it requires transfer of radioisotope to the operating
theatre, is not as reliable and is complicated by radiation
safety issues.
Pathology
The role of the pathology laboratory is pivotal to the
success of the procedure. In particular the development
of multisectioning and immunohistochemistry (IHC)
staining techniques has been reported to increase the rate
of detection of malignant disease by up to 33% [66–68].
IHC can be particularly beneficial in patients with
invasive lobular cancer [69,70]. Trials currently in progress
aim to determine the significance of IHC detected
micrometastases in patients treated by conventional
pathological criteria [71]. It has been shown recently that
patients with favourable breast cancer histology have only
a small risk of axillary sentinel lymph node metastases
and that biopsy is not necessary in all these patients [72].
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Radiation safety
Several papers have discussed various aspects of radiation
safety associated with the sentinel node in detail [73–78].
Radiation doses are low and no additional procedures are
required for the protection of staff. The procedure can be
performed safely during pregnancy as the foetal dose is
very low.
Clinical issues
The procedure is not contraindicated in patients with
clinically palpable axillary nodes [18]. Relative contraindi-
cations include prior axillary surgery and subglandular
breast implants. In one centre, more than 50 patients with
subpectoral implants have been associated with 100%
SLN identification success rate and no clinically detected
recurrences in patients with negative SLN biopsy [8].
For patients with a primary tumour greater than 4 cm,
the success of SLNB shows little difference to those
with smaller tumours [12]. In patients with multifocal
breast cancer, sentinel node identification has been
reported in 94% and is an accurate predictor of nodal
status [79]. This type of cancer favours a periareolar or
subareolar injection protocol. SLNB performed following
excisional biopsy demonstrates satisfactory results [29,80].
Patients with ductal carcinoma-in-situ (DCIS) have an
excellent long term prognosis (98% survival) but 10%–
29% of these patients will have invasive cancer at
definitive surgery [81–87]. Analysis of resected nodes from
patients who had negative axillary surgery previously,
demonstrated micrometastases in 13% of nodes but none
in patients who had disease recurrence [88]. This would
indicate that SNLB is not necessary in these patients.
False negative rate
The false negative rate is the percentage of node positive
patients who are missed by mapping [8]. In one centre
there has been no axillary recurrence (mean 5 years)
following a negative node biopsy in 1914 patients [8].
Data from case control studies to date indicate SLN
biopsy to be highly predictive of axillary node status with
a false negative rate of less than 5% [89]. Reasons for
false negative results are attributed to changes in surgical
personnel, difficult lymph node location and absence
of a thorough histological study [90]. Factors militating
against sentinel node identification are increasing age and
body mass index [91]. A review of ten large observational
studies revealed just ten axillary recurrences in 2664
patients (0.4%) who did not undergo ALND following
negative SLN biopsy [43]. A large recent study comprising
4008 patients and a median follow-up of 31 months had
an overall axillary recurrence rate of 0.25% [92]. A further
study in 234 patients (median follow-up 42 months) did
not find an increased rate of axillary recurrence in patients
with negative SLN or SLN micrometastases [93]. As the
axillary recurrence rate should not exceed that seen after
conventional axillary clearance surgery (1.0%–2.3%), the
figures quoted above compare very favourably [94–96].
Internal mammary and intramammary lymph
nodes
Intramammary nodes with metastases have been doc-
umented as independent predictors of poor outcome
for patients with breast cancer [97]. In one centre
analysing the results of 640 patients, 94% demonstrated
a sentinel node in the ipsilateral axilla and 46% also
had sentinel nodes outside the axilla [34]. In 5% of
patients drainage was exclusively to non-axillary sentinel
nodes. The most important non-axillary drainage was
to the internal mammary nodal chain and 40% of
patients demonstrated a sentinel node in this area [34].
Sentinel lymph node biopsy of internal mammary nodes
is associated with a low morbidity and has been shown
to improve staging and change treatment strategy [98,99].
Proponents of evaluating internal mammary nodes argue
that this supports lymphatic mapping as it provides more
accurate staging although its impact on outcome is less
clear [100,101]. Nonetheless, it has been demonstrated that
metastases in the internal mammary nodes influence
survival in a manner comparable to that of metastases
in axillary lymph nodes [102]. A review with 30 years
of results demonstrated that patients with isolated IMN
disease have a prognosis equivalent to that of patients
with isolated axillary metastases [103]. A combination of
metastatic disease in both axillary and internal mammary
nodal chains has an especially poor prognosis with a
10-year survival of 37% [104]. Internal mammary nodes
identified on preoperative lymphoscintigraphy require
histopathological confirmation of disease before therapy
is commenced [105]. Internal mammary nodes are best
identified when peritumoural, intratumoural or subtu-
moural injections are made with some reports visualising
these nodes in 10%–30% of patients whereas subdermal,
intradermal, periareolar or subareolar injections result in
much less frequent visualisation of these nodes [47,58].
Micrometastases
Micrometastases are defined as tumour deposits in
nodes ranging from 0.2 to 2 mm with cells less than
0.2 mm known as isolated tumour cells [106]. Despite
the evidence of some retrospective studies there is
controversy regarding the prognostic significance of
micrometastases found only by immunohistochemistry
staining, particularly when only isolated tumour cells are
found [71]. A literature review on the clinical significance
of micrometastases concluded that they were associated
with a poorer prognosis than that associated with no
axillary involvement [107]. In a study involving a 15-year
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follow-up on almost 100 patients and 1539 axillary
lymph nodes with pT1 breast cancer determined that
half of the patients developed distant metastases [108].
However, recent studies involving 234 patients and
84 patients (median follow-up 42 and 40 months,
respectively) showed that micrometastases were not
associated with an increased risk of axillary recurrence or
that outcome was significantly affected by the presence of
micrometastases [93,109]. Micrometastases are not reliably
detected by FDG-PET imaging [110,111].
Neoadjuvant therapy
In published work to date the SLN identification rate has
ranged from 84% to 97% implying that the accuracy of
sentinel node biopsy is not influenced by neoadjuvant
therapy [112–121]. Questions remain as to whether all
nodes respond equally to therapy and a high false negative
rate (up to 33%) has been reported in some of these series.
Pending further clarification, it is still probably best to
perform SLNB prior to commencement of neoadjuvant
therapy.
Summary
Lymphatic mapping for breast cancer is rapidly becoming
the standard of care but there is no single study that
demonstrates conclusively which particular sentinel node
protocol is best for a specific patient. The results from
three multicentre trials sponsored by the National Cancer
Institute (due to report in 2007) attempting to answer
some of the issues discussed above are eagerly awaited.
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Abstract
Breast cancer is the most common cancer affecting women. In the screening of women for breast cancer,
mammography is the most used imaging modality. Women with an increased risk for getting breast cancer can develop
a malignancy at a relatively young age compared to other women. The increased risk for developing breast cancer can
usually be found in a positive familial history. This positive familial history is based on a gene mutation in 5–10%
of cases. The most common gene mutations are BRCA1 and BRCA2. This risk makes it necessary to start screening
these women at a young age. Mammography, however, has proven to be less reliable in younger women because
its sensitivity is lowered due to the dense breast tissue often present in this group. MRI has a higher sensitivity for
detecting breast cancer compared to mammography. MRI is not influenced by the density of the breast tissue. This
makes breast MRI the best modality available for the screening of women with an increased risk for developing breast
cancer.
Keywords: Breast; cancer; screening; high risk.
Introduction
Breast cancer is the most common cancer affecting
women and has an enormous impact on their health. The
incidence of breast cancer varies between countries with
the highest incidence in the United States and Northern
Europe. In the United States breast cancer makes up 30%
of all cancers in women, while in The Netherlands the
lifetime risk for a woman for developing breast cancer is
about 11% [1].
The aetiology of breast cancer is varied: inherited
genetic susceptibility, acquired genetic changes, and
effects of endogenous and exogenous environment
factors. The interactions of all these factors contribute to
the development of breast cancer.
There is limited and indirect evidence that self-
examination and physical examination can help in
decreasing mortality because tumours smaller than
10 mm will not be detected in the majority of the cases [2].
Most breast cancers are detected with mammography
in either a screening situation or by the discovery of
a palpable breast mass. The smaller the tumour is at
detection, the better the prognosis [3].
Randomised trials have shown that screening with
mammography in the age category of 50–70 years
can reduce mortality by about 25%. However, there
is no consensus at the moment about the value of
screening younger women with mammography. One of
the reasons is the lower sensitivity of mammography
in women below the age of 50 years. This is because
young, pre-menopausal, women have denser breasts
compared to post-menopausal women, resulting in an
increased chanced that a malignancy will be missed on
mammography [4].
In a diagnostic setting, magnetic resonance imaging
(MRI) is a very sensitive tool for the detection of
breast cancer. Especially for invasive breast cancer, the
sensitivity of this imaging technique is reported to be
above 95% [5]. This sensitivity is not influenced in any
way by the amount of glandular tissue present in the
breast. However the specificity of this modality is only
moderate. The role of MRI as a screening modality has
not yet been outlined. In the literature, MRI has only been
evaluated as a screening tool for women with an increased
risk for developing breast cancer [6–8]. In this paper the
role of MRI in the screening of women with an increased
risk for developing breast cancer is discussed.
Increased risk for breast cancer
There are two categories of women who have an
increased risk for developing breast cancer.
The first group are those with a family history of breast
cancer. Approximately 20%–30% of women with breast
cancer have a positive family history and about 20% of
these individuals have a first degree relative with breast
cancer [9]. Only about 5%–10% of all cases of breast
cancer are caused by inherited factors. The most common
gene mutations are the BRCA1 and BRCA2.
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In 1990, Hall and co-workers identified chromosome
17 q 21 as the location of a susceptibility gene for
early onset breast cancer, now known as the BRCA1
gene mutation [10]. Shortly after that Narod [11] described
a linkage between the genetic marker D17 S 74 on 17
q 21 and ovarian cancer. In two different studies the
suggestion has been made that about 3% of all breast
cancers are caused by the BRCA1 gene [12,13] and about
45% of all hereditary cases of breast cancer are caused
by the BRCA1 mutation. Mutations in the BRCA1 are
most commonly seen in Russia, followed by Israel and
Italy [14]. Women who are carriers of the BRCA1 gene
mutation have a lifetime risk (LTR) for developing breast
cancer of approximately 80%. Exogenous hormone and
carcinogen exposure are also risk-modifying factors in
this group.
Other malignancies suggested to have an increased
prevalence in these families are ovarian cancer, prostate
and colonic cancer [12]. BRCA1 associated breast malig-
nancies tend to have a high malignancy grade and are
often oestrogen and progesterone receptor negative. The
tumour is also highly proliferative [15]. Median age of
onset of breast cancer in this group is younger than 45
years [16].
Approximately 35% of all inherited breast cancers
are caused by the BRCA2 mutation, first identified
by Wooster et al. [17]. They also described a linkage
between BRCA2 mutation and male breast cancer. The
estimated LTR for developing breast cancer in this group
is somewhat lower than in the BRCA1 group. It has
been suggested by Ursin [18] that in this group the use of
oral contraceptives also increases the risk for developing
breast cancer.
A variety of other malignancies are associated with
the BRCA2 carriers. Non-Hodgkin’s lymphoma has
been reported and also prostate cancer and bladder
cancer [19,20]. The BRCA2 mutation is associated with a
6% LTR of male breast cancer [21], which means a 100-
fold increase over the general male population. At the
moment little is known about the malignancy grade and
receptor status in the BRCA2 group [15].
For both the BRCA1 and BRCA2 mutation carriers, the
LTR for a contralateral breast cancer is about 65% [15].
There are other more sporadic hereditary diseases with
an increased risk for developing breast cancer. The Li–
Fraumeni syndrome was first identified in 1969 [22]. It
is an autosomal dominant disease causing an increased
risk for developing among others breast cancer, different
types of sarcoma and leukaemia. In this group 30% of
all malignancies occur before the age of 15. Cowden’s
disease or multiple hamartoma syndrome showed an
increased risk for both benign breast disorders like
fibroadenomas and nipple malformations and breast
malignancies [23,24]. Other hereditary diseases such as
ataxia telangiectasia and the Peutz–Jeghers syndrome
(hamartomous polyps in the small bowel) and the Muir–
Torre syndrome (a variant of hereditary non-polyposis
colon cancer) also give an increased risk for breast
cancer [25].
Another group of women with an increased risk
for breast cancer consists of women who have an
individual risk factor. Patients with a history of lobular
carcinoma in situ (LCIS) have a somewhat increased
incidence of developing an invasive cancer. The National
Surgical Adjuvant Breast and Bowel Project (NSABBP)
suggested an incidence of 13 invasive malignancies in
1000 women with an LCIS [26]. In this group there is
also a risk for bilateral breast cancer. Ductal carcinoma
in situ (DCIS) also gives an increased risk for an
invasive breast malignancy. About 30% of women
not treated postoperatively with irradiation developed
an invasive malignancy after a mean interval of 6
years [27,28]. Invasive lobular carcinoma is characterized
by multifocality in the ipsilateral breast and appears to
be more often bilateral [29] than other types of invasive
malignancies [30].
In the updated results of the nurses’ Health Study, post-
or per-menopausal use of hormones showed an excess
risk for developing breast cancer in the group of women
with current or recently used hormones [31]. The risk
increased with increasing duration.
Women treated with irradiation of the chest for,
for instance, (non-)Hodgkin’s lymphoma, also have an
increased risk for developing breast cancer. The excess
risk in this category of patients is dependent on dose
and age at irradiation. The younger the age at time of
exposure to irradiation, the younger the onset of breast
cancer [32].
Screening of the breast
Currently there are four possible breast screening modali-
ties: clinical examination, mammography, ultrasound and
MRI. The primary goal of breast examinations during
screening is the detection of breast cancer at an as early
stage as possible in order to reduce mortality.
Clinical examinations of the breasts and self-
examination as a screening procedure have been poorly
evaluated. There is only limited and indirect evidence
that these methods could help in decreasing mortality
due to breast cancer [2]. As mentioned, small malignant
lesions (<10 mm) will not be detected by palpation in
the majority of cases. Kriege and co-workers showed a
sensitivity of only 17.8% of clinical breast examination
in a screening setting [6].
The most used imaging tool for screening at the
moment is mammography. The sensitivity of mammog-
raphy increases with the age of the woman. The younger
the woman, the more glandular tissue there is, the
denser the breasts are, and the lower the sensitivity
of mammography. For women in the age group 40–50
sensitivity ranges from about 50% to 80%, while in the
age group over 50 the sensitivity ranges from 70% to
about 90% [33]. The sensitivity of mammography in the
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Figure 1 (a), (b) The mammography of a 39-year-old woman obtained during annual screening because of a
familial history of breast cancer. No abnormalities were seen. (c) The MRI examination obtained on the same
day. Strong irregular enhancement in the medial part of the left breast was detected. Pathology revealed a
DCIS grade 3.
case of invasive lobular carcinoma (ILC) is lower than in
women with invasive ductal carcinoma (IDC) [30].
In 1973, the breast cancer detection demonstration
project (BCDDP) was started. In the subsequent 7 years
more than 280 000 women were screened. The screening
depicted about half of all breast cancers detected in the
screened area. In addition, the distribution of stage was
more favourable in the screened population than in a
control group in that area, so overall long-term survival
was also better [34]. In 1998 in the Netherlands a mortality
reduction of 13% was reached in the age category
55–74 since the beginning of screening in 1990 with
conventional mammography [35]. Other screening trials
like the health insurance plan of New York (HIP-study)
showed a mortality reduction of 30% in the screened
group compared to the control group. Analysis of age
specific mortality reduction indicates that screening for
breast cancer has a special benefit in older women above
the age of 50 and less in the younger age group. In
addition, Tabar et al. showed that the likelihood of
dedifferentiation of a tumour is much higher in women
younger than 40 years [36]. Survival is also influenced by
both tumour grade and the size of the tumour [36,37].
There is currently no evidence that ultrasound (US) has
a role as a screening modality for breast cancer. The two
most important roles of US are differentiation between
cystic and solid lesions in the breast and US guided
biopsy of solid breast lesions.
MRI of the breast is nowadays mostly performed
as a dynamic investigation. The most currently used
investigation technique is the FLASH 3D technique
which includes one series of images pre-contrast and
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Figure 2 (a), (b) The mammography of a 32-year-old woman obtained during annual screening because of
a proven BRCA2 gene carrier. Very dense glandular tissue was seen on mammography. (c) The MRI from the
same day. In the medial part of the right breast an irregular strong enhancing area was seen. Pathology showed
an invasive duct carcinoma.
five series of images after intravenous administration
of contrast medium containing gadolinium. MR images
are evaluated according to morphology and kinetic
behaviour of the lesions [38]. Smoothly outlined round or
oval lesions tend more to be benign, while speculated
lesions are more suspicious of a malignancy. If a lesion
shows a wash out on kinetic behaviour, this is highly
suspicious for a malignancy. If there is progress in signal
intensity over time this is more characteristic for a benign
lesion [38]. Although the sensitivity of MRI for detecting
invasive breast cancer is more than 95%, the value in
detecting DCIS, especially DCIS grade I, is lower [39].
DCIS grade 3 can usually be detected on MRI (Fig. 1).
The sensitivity for DCIS is described by Orel et al. [40]
to be in the range of 75%. Three grade I DCIS were
missed. This is in comparison to the results of Boetes
et al. [41], who also described a sensitivity of about 75%
in this group. In a series of 17 patients, they missed four
cases of DICS, 3 grade I and 1 grade III. The problem
with screening with MRI is the relatively low specificity,
which means a relatively high number of false-positive
findings. Almost all women with a genetic predisposition
for developing breast cancer are younger than the age
of 50. So the value of screening with conventional
mammography is doubtful in this group of women.
Especially in young women in a screening situation it
is important to diagnose a malignancy as early as possible
to increase survival.
Kuhl was the first to describe the results of MRI
in a screening situation for women with an increased
risk for developing breast cancer [7]. A group of
192 asymptomatic and six symptomatic women were
evaluated. In the symptomatic group, MRI detected all
malignancies. In the asymptomatic group of women, nine
malignancies were found. MRI detected all nine, whereas
mammography combined with US detected only four.
In the same year Tilanus-Linthorst described an
asymptomatic group of 109 women with a 25% or
more lifetime risk, in which 12 gene carriers also were
included. In this group MRI detected three malignancies
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occult on mammography [42]. A retrospective study in
2001 by Stoutjesdijk et al., evaluated 75 women, of whom
20% were proven gene carriers. Thirteen malignancies in
this group showed a cancer on MRI while mammography
detected five [43].
In 2003, Morris and co-workers described a group
of 367 women, retrospectively. MRI detected 14 more
malignancies than mammography [44].
In 2004, the results of screening a group of 1909
women with both MRI and mammography were
described by Kriege et al. [6]. In the LTR group of 15%–
30%, the detection rate for cancer was 7.8 per 1000
women, in the LTR of 30%–50% the detection rate
was 5.4 per 1000. However, in the group of carriers
of BRCA1/2 the incidence of malignancy was 26.5 per
1000 women. The overall sensitivity for the detection of
breast cancer was 40% for mammography and 71.5% for
MRI (Fig. 2). If only the invasive cancers were taken
into account the sensitivity of mammography dropped to
33% and of MRI increased to 79%. In the MRISK study
group 43% of all invasive malignancies were smaller that
10 mm, but in two selected control groups only, 14 and
12.5%, the tumour was smaller than 10 mm. The negative
node status was also better in the MRISK group than in
both control groups with 21.4% compared to 52.4 and
56.4%, respectively.
The results for the MRISK study group are confirmed
by the MARIBS study [8]. They evaluated 649 women
with a total of 1881 screens both with mammography
and MRI. Sensitivity of mammography was 40% and for
MRI this was 77%. The combination of both imaging
techniques showed a sensitivity of 94%. The difference
in sensitivity was especially seen in the gene carrier
group. However, as stated by Liberman [45], any method
of screening for breast cancer has the potential for both
benefit and harm. Harm are the costs, anxiety, follow-up
imaging and benign biopsies. The benefit of screening
is especially the detection of a malignancy as early as
possible. This may give a mortality reduction. Although
prognosis of small breast cancers is better, the detection
of a small cancer does not guarantee an improved survival
rate. The real value of screening can only be proved by
randomized controlled trials with death as an end point.
However, this is no longer possible. The data published
to date show that screening with MRI has benefit for
the group of women at high risk for developing breast
cancer. However, if a centre proceeds to screen with MRI
it should follow technical and interpretative guidelines
and there should be the possibility of performing MR
guided biopsies [46,47].
Conclusion
In the screening of women with an increased risk for
developing breast cancer detection needs to be done at a
young age. Therefore mammography is of limited value.
Because the sensitivity of MRI is high for detecting
breast cancer and because this sensitivity is not influenced
by the amount of glandular tissue present, as with
mammography, MRI is the best modality available at this
time for the screening of women with an increased risk
for developing breast cancer.
References
[1] Visser O, Coebergh JWW, van Dijck JAAM et al., eds.
Incidence of Cancer in the Netherlands 1998. Utrecht, the
Netherlands: Netherlands Cancer Registry, 2002.
[2] Baines CJ, Miller AB, Bassett AA. Physical examination.
Its role as a single screening modality in the Canadian
National Breast Screening Study. Cancer 1989; 63:
1816–22.
[3] Chu KC, Tarone RE, Kessler LG et al. Recent trends in
US breast cancer incidence, survival, and mortality rates.
J Natl Cancer Inst 1996; 88: 1571–9.
[4] Nystrom L, Andersson I, Bjurstam N, Frisell J, Nor-
denskjold B, Rutqvist LE. Long-term effects of mam-
mography screening: updated overview of the Swedish
randomised trials. Lancet 2002; 359: 909–19.
[5] Bedrosian I, Schlencker J, Spitz FR et al. Magnetic
resonance imaging-guided biopsy of mammographically
and clinically occult breast lesions. Ann Surg Oncol 2002;
9: 457–61.
[6] Kriege M, Brekelmans CT, Boetes C et al. Efficacy of
MRI and mammography for breast-cancer screening in
women with a familial or genetic predisposition. N Engl
J Med 2004; 351: 427–37.
[7] Kuhl CK, Schmutzler RK, Leutner CC et al. Breast MR
imaging screening in 192 women proved or suspected to
be carriers of a breast cancer susceptibility gene: prelimi-
nary results. Radiology 2000; 215: 267–79.
[8] Leach MO, Boggis CR, Dixon AK et al. Screening with
magnetic resonance imaging and mammography of a
UK population at high familial risk of breast cancer: a
prospective multicentre cohort study (MARIBS). Lancet
2005; 365: 1769–78.
[9] Newman B, Mu H, Butler LM, Millikan RC, Moor-
man PG, King MC. Frequency of breast cancer
attributable to BRCA1 in a population-based series of
American women. JAMA 1998; 279: 915–21.
[10] Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA,
Huey B, King MC. Linkage of early-onset familial
breast cancer to chromosome 17q21. Science 1990; 250:
1684–9.
[11] Narod SA, Feunteun J, Lynch HT et al. Familial breast-
ovarian cancer locus on chromosome 17q12-q23. Lancet
1991; 338: 82–3.
[12] Struewing JP, Hartge P, Wacholder S et al. The risk of
cancer associated with specific mutations of BRCA1 and
BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:
1401–8.
[13] Whittemore AS, Gong G, Itnyre J. Prevalence and
contribution of BRCA1 mutations in breast cancer and
ovarian cancer: results from three US population-based
case-control studies of ovarian cancer. Am J Hum Genet
1997; 60: 496–504.
[14] Szabo CI, King MC. Population genetics of BRCA1 and
BRCA2. Am J Hum Genet 1997; 60: 1013–20.
Multidisciplinary symposium: breast cancer S15
[15] DeMichelle A, Weber BL. Inherited genetic factors.
In: Diseases of the Breast. Harris JR, Lippman ME,
Morrow M et al., eds. Philadelphia, PA: Lippincott
Williams and Wilkins, 1999: 221–36.
[16] Easton DF, Bishop DT, Ford D, Crockford GP. Genetic
linkage analysis in familial breast and ovarian cancer:
results from 214 families. The Breast Cancer Link-
age Consortium. Am J Hum Genet 1993; 52: 678–701.
[17] Wooster R, Neuhausen SL, Mangion J et al. Localization
of a breast cancer susceptibility gene, BRCA2, to
chromosome 13q12-13. Science 1994; 265: 2088–90.
[18] Ursin G, Henderson BE, Haile RW et al. Does oral
contraceptive use increase the risk of breast cancer in
women with BRCA1/BRCA2 mutations more than in
other women? Cancer Res 1997; 57: 3678–81.
[19] Schubert EL, Lee MK, Mefford HC et al. BRCA2 in
American families with four or more cases of breast or
ovarian cancer: recurrent and novel mutations, variable
expression, penetrance, and the possibility of fami-
lies whose cancer is not attributable to BRCA1 or
BRCA2. Am J Hum Genet 1997; 60: 1031–40.
[20] Teng DH, Bogden R, Mitchell J et al. Low incidence of
BRCA2 mutations in breast carcinoma and other cancers.
Nat Genet 1996; 13: 241–4.
[21] Wooster R, Bignell G, Lancaster J et al. Identification
of the breast cancer susceptibility gene BRCA2. Nature
1995; 378: 789–92.
[22] Li FP, Fraumeni Jr JF, Mulvihill JJ et al. A cancer family
syndrome in twenty-four kindreds. Cancer Res 1988; 48:
5358–62.
[23] Brownstein MH, Wolf M, Bikowski JB. Cowden’s
disease: a cutaneous marker of breast cancer. Cancer
1978; 41: 2393–8.
[24] Starink TM. Cowden’s disease: analysis of fourteen new
cases. J Am Acad Dermatol 1984; 11: 1127–41.
[25] Jeghers H, McKusick VA, Katz KH. Generalized intesti-
nal polyposis and melanin spots of the oral mucosa, lips
and digits; a syndrome of diagnostic significance. N Engl
J Med 1949; 241: 993.
[26] Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen
for prevention of breast cancer: report of the National
Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst 1998; 90: 1371–88.
[27] Page DL, Dupont WD, Rogers LW, Landenberger M.
Intraductal carcinoma of the breast: follow-up
after biopsy only. Cancer 1982; 49: 751–8.
[28] Page DL, Dupont WD, Rogers LW, Jensen RA,
Schuyler PA. Continued local recurrence of carcinoma
15–25 years after a diagnosis of low grade ductal
carcinoma in situ of the breast treated only by biopsy.
Cancer 1995; 76: 1197–200.
[29] Contesso G, Mouriesse H, Friedman S, Genin J,
Sarrazin D, Rouesse J. The importance of histologic grade
in long-term prognosis of breast cancer: a study of 1010
patients, uniformly treated at the Institut Gustave-Roussy.
J Clin Oncol 1987; 5: 1378–86.
[30] Boetes C, Veltman J, van DL, Bult P, Wobbes T,
Barentsz JO. The role of MRI in invasive lobular
carcinoma. Breast Cancer Res Treat 2004; 86: 31–7.
[31] Colditz GA, Hankinson SE, Hunter DJ et al. The use of
estrogens and progestins and the risk of breast cancer
in postmenopausal women. N Engl J Med 1995; 332:
1589–93.
[32] Hancock SL, Tucker MA, Hoppe RT. Breast cancer after
treatment of Hodgkin’s disease. J Natl Cancer Inst 1993;
85: 25–31.
[33] Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S.
Report of the International Workshop on Screening
for Breast Cancer. J Natl Cancer Inst 1993; 85: 1644–56.
[34] Bassett LW, Liu TH, Giuliano AE, Gold RH. The preva-
lence of carcinoma in palpable vs. impalpable, mammo-
graphically detected lesions. AJR Am J Roentgenol 1991;
157: 21–4.
[35] National Evaluation Team for Breast Cancer Screen-
ing. Nationwide breast cancer screening fully accom-
plished; results from the implementation phase 1990–
1997. Ned Tijdschr Geneeskd 2000; 144: 1124–9.
[36] Tabar L, Duffy SW, Burhenne LW. New Swedish breast
cancer detection results for women aged 40–49. Cancer
1993; 72(Suppl 4): 1437–48.
[37] Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A,
Grontoft O. Update of the Swedish two-county program
of mammographic screening for breast cancer. Radiol
Clin North Am 1992; 30: 187–210.
[38] Kuhl CK. MRI of breast tumors. Eur Radiol 2000; 10:
46–58.
[39] Boetes C, Mus RD, Holland R et al. Breast tumors:
comparative accuracy of MR imaging relative to mam-
mography and US for demonstrating extent. Radiology
1995; 197: 743–7.
[40] Orel SG, Mendonca MH, Reynolds C, Schnall MD,
Solin LJ, Sullivan DC. MR imaging of ductal carcinoma
in situ. Radiology 1997; 202: 413–20.
[41] Boetes C, Strijk SP, Holland R, Barentsz JO, Van
Der Sluis RF, Ruijs JH. False-negative MR imaging of
malignant breast tumors. Eur Radiol 1997; 7: 1231–4.
[42] Tilanus-Linthorst MM, Obdeijn IM, Bartels KC,
de Koning HJ, Oudkerk M. First experiences in screening
women at high risk for breast cancer with MR imaging.
Breast Cancer Res Treat 2000; 63: 53–60.
[43] Stoutjesdijk MJ, Boetes C, Jager GJ et al. Magnetic
resonance imaging and mammography in women with a
hereditary risk of breast cancer. J Natl Cancer Inst 2001;
93: 1095–102.
[44] Morris EA, Liberman L, Ballon DJ et al. MRI of occult
breast carcinoma in a high-risk population. AJR Am J
Roentgenol 2003; 181: 619–26.
[45] Liberman L. Breast cancer screening with MRI—what are
the data for patients at high risk? N Engl J Med 2004; 351:
497–500.
[46] Veltman J, Boetes C, Wobbes T, Blickman JG,
Barentsz JO. Magnetic resonance-guided biopsies and
localizations of the breast: initial experiences using an
open breast coil and compatible intervention device.
Invest Radiol 2005; 40: 379–84.
[47] Viehweg P, Heinig A, Amaya B, Alberich T, Lani-
ado M, Heywang-Kobrunner SH. MR-guided interven-
tional breast procedures considering vacuum biopsy in
particular. Eur J Radiol 2002; 42: 32–9.
